科伦博泰生物-B今日盘中大涨5.03%，引起了市场的广泛关注。
消息面上，瑞银发表研究报告指出，科伦博泰生物-B去年下半年收入同比增长101%，符合预期；净亏损好于预期；毛利率提升至74%。尽管瑞银下调了其目标价及部分盈利预测，但报告重申了“买入”评级，这增强了市场对公司基本面的信心。
报告显示，公司毛利率的提升主要受产品销售占比提高带动。瑞银预计，随着今年更多第三期临床数据释出，公司可能获得潜在的里程碑付款，从而带来授权收入。
科伦博泰生物-B今日盘中大涨5.03%，引起了市场的广泛关注。
消息面上，瑞银发表研究报告指出，科伦博泰生物-B去年下半年收入同比增长101%，符合预期；净亏损好于预期；毛利率提升至74%。尽管瑞银下调了其目标价及部分盈利预测，但报告重申了“买入”评级，这增强了市场对公司基本面的信心。
报告显示，公司毛利率的提升主要受产品销售占比提高带动。瑞银预计，随着今年更多第三期临床数据释出，公司可能获得潜在的里程碑付款，从而带来授权收入。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.